A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT07729475
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT07729475
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07729475. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-27 (anticipated); primary completion 2026-12-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
- Condition
- Elevated Lipoprotein(a)
- Intervention (Drug)
- SAL0137 Dose 1
- Intervention (Drug)
- SAL0137 Dose 2
- Intervention (Drug)
- SAL0137 Dose 3
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct07729475- Content hash
6d4dd9f43074f35dfc2120e58123d33abba9dc3fb1a348cfb13319a9474d1600